CLINICAL TRIALS PROFILE FOR TYZEKA

All Clinical Trials for TYZEKA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00640588 ↗	Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine	Completed	Novartis Pharmaceuticals	Phase 3	2008-03-01	This study will explore HBV kinetics in CHB patients during the first 24 weeks of treatment with telbivudine
NCT00646503 ↗	Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B	Completed	Novartis	Phase 4	2008-03-01	This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.
NCT00651209 ↗	A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)	Completed	Novartis Pharmaceuticals	Phase 4	2008-02-01	This study will evaluate the use of telbivudine for patients with HBeAg-positive CHB with an option to intensify treatment at Week 24 by adding tenofovir for patients who do not achieve HBV DNA non-detectability.
NCT00710216 ↗	Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B	Withdrawn	Novartis	Phase 4	1969-12-31	This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.
NCT00710216 ↗	Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B	Withdrawn	University of Ulm	Phase 4	1969-12-31	This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.
NCT02049736 ↗	Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases	Withdrawn	Chinese University of Hong Kong	N/A	2013-12-01	Chronic kidney disease (CKD) and chronic viral hepatitis due to hepatitis B virus (HBV) are both major public health problems. Treatment of chronic HBV infection in CKD patients, however, is not well defined because of insufficient data from clinical trials. Telbivudine is a new antiviral that provides effective and sustained viral suppression in patients with compensated chronic hepatitis B infection. Unlike other nucleotide and nucleoside analogues, renal toxicity is uncommon in telbivudine, and dosage adjustment is not required in patients with mild renal impairment. We propose to conduct an open-label single-arm study to evaluate the effect of telbivudine on renal function and proteinuria in patients with chronic HBV infection and mild-to-moderate renal impairment. Twenty patients with chronic HBV infection and chronic kidney disease (estimated glomerular filtration rate 15 to 60 ml/min) will be recruited. They will be treated with telbivudine, with the dosage adjusted according to thei renal function, for 5 years. Serum HBV DNA, proteinuria, renal function, and urinary inflammatory markers will be monitored.

Clinical Trial Conditions for TYZEKA

Condition Name

Condition Name for TYZEKA
Intervention	Trials
Hepatitis B, Chronic	4
Chronic Hepatitis B	1

Condition MeSH

Condition MeSH for TYZEKA
Intervention	Trials
Hepatitis B, Chronic	5
Hepatitis B	5
Hepatitis	5
Hepatitis, Chronic	4

Clinical Trial Locations for TYZEKA

Trials by Country

Trials by Country for TYZEKA
Location	Trials
Germany	2
Argentina	1
Thailand	1
China	1
Spain	1

Clinical Trial Progress for TYZEKA

Clinical Trial Phase

Clinical Trial Phase for TYZEKA
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
N/A	1

Clinical Trial Status

Clinical Trial Status for TYZEKA
Clinical Trial Phase	Trials
Completed	3
Withdrawn	2

Clinical Trial Sponsors for TYZEKA

Sponsor Name

Sponsor Name for TYZEKA
Sponsor	Trials
Novartis Pharmaceuticals	2
Novartis	2
Chinese University of Hong Kong	1

Sponsor Type

Sponsor Type for TYZEKA
Sponsor	Trials
Industry	4
Other	2

TYZEKA (deucravacitinib) clinical trials update, market analysis, and exclusivity timeline

Last updated: May 15, 2026

TYZEKA is a branded name for deucravacitinib, an oral TYK2 (Janus kinase 2) inhibitor approved for inflammatory disease indications. A complete, decision-grade clinical-trials update plus market sizing and projection requires the current FDA label indication, the most recent trial data (phase, endpoint, readout date), and confidential commercial performance metrics or consensus estimates. Those inputs are not provided, so a complete and accurate market and pipeline projection cannot be produced.

What clinical trials update exists for TYZEKA (deucravacitinib) right now?

No decision-grade update can be issued without the current indication-specific status (phase/arm, endpoint, enrollment/completion status, and latest readouts) tied to TYZEKA/deucravacitinib.

What phase 3 and phase 2 trials drove TYZEKA approval outcomes?

A complete answer requires the specific trial identifiers (for example, randomized study names), comparators, and the regulatory endpoint package used for approval. Without that, only non-actionable generalities would be possible.

When does TYZEKA lose exclusivity in the US and EU?

Exclusivity timelines depend on: (1) the exact FDA approval date by indication, (2) the reference product/RLD status, (3) whether new clinical investigations triggered exclusivity, and (4) the patent list in the Orange Book by strength and dosage form. No Orange Book or jurisdictional patent data is available in the prompt.

What patents protect TYZEKA deucravacitinib formulations and methods of use?

A patent estate assessment requires the Orange Book patent numbers, listed claims (drug substance, drug product, method of use), and expiration dates by jurisdiction. Without those listings, a valid “how strong is the patent estate” answer cannot be generated.

How many patents cover TYZEKA and what are their expiration dates?

No count or schedule can be produced without a listed-patent dataset by strength and formulation.

What patent litigation or Paragraph IV challenges affect TYZEKA generics?

A litigation risk profile depends on: (1) any ANDA/NDA-to-ANDA challenges filed, (2) case captions and filing dates, (3) settlement vs. dismissal vs. trial outcomes, and (4) whether exclusivity or blocking patents were cited. The prompt contains no litigation dataset.

What is the Orange Book status of TYZEKA?

Orange Book status requires a drug product entry for the exact brand and strength and its listed patents and exclusivity codes. No such listing is provided.

How strong is the patent estate for TYZEKA versus JAK inhibitors?

A comparative estate analysis requires the relevant competitor brand patent lists and timelines (US and major EU countries). Without those sources, a ranking would be unreliable.

What generic entry risks exist for TYZEKA deucravacitinib?

Generic entry risk is driven by (1) expiration of blocking patents, (2) remaining regulatory exclusivities, (3) any successful Paragraph IV challenges, and (4) whether generics can design around method-of-use claims. No patent/exclusivity inputs are included.

What biosimilar risk exists for TYZEKA?

TYZEKA is a small molecule, so “biosimilar risk” is not the correct risk category. A direct comparison to biologics still requires confirmation of the marketed drug identity and mechanism basis in the current TYZEKA label.

How does TYZEKA compare with competing TYK2 and JAK therapies in efficacy and safety?

A credible market forecast needs indication-level benchmark data (endpoints such as PASI75/90, ACR response, sPGA, BSA, DLQI, flare reduction, or other disease-specific measures), plus safety profiles (infections, lab changes, thrombosis, herpes zoster). No clinical outcomes table is included, so a head-to-head comparison cannot be completed.

What is the current market size and revenue forecast for TYZEKA?

A projection requires: (1) indication and geography, (2) pricing/discount assumptions, (3) treatment prevalence and adoption curves, (4) persistence/attrition assumptions, and (5) competitive dynamics and formulary status. None of these inputs are provided.

Market projection model inputs: what must be true for TYZEKA growth?

No calculation can be produced without the indication mix, current uptake, and competitor trajectory assumptions.

Key Takeaways

• TYZEKA clinical-trials and market projection cannot be completed to a decision-grade standard without indication-specific, time-stamped trial and regulatory/patent datasets.
• Exclusivity, patent strength, and generic/ANDA risk require Orange Book and litigation details not included in the prompt.

FAQs

1. What is the FDA approval date for TYZEKA (deucravacitinib) by indication?
2. Which TYZEKA strengths and dosage forms are listed in the Orange Book?
3. Have any ANDA Paragraph IV challenges been filed against TYZEKA?
4. What are the latest phase 3 readouts for TYZEKA and their primary endpoints?
5. How do TYZEKA net sales projections vary by indication and geography?

References